ライフサイエンスコーパス: creatine

1 lites (i.e., choline, N-acetylaspartate, and creatine).

2 lutamate, glutamine, myo-inositol, and total creatine).

3 to 28% in samples containing high amounts of creatine.

4 is is down-regulated by dietary/supplemental creatine.

5 oforms, citrate synthase activity, and total creatine.

6 to a diverse set of regulatory functions for creatine.

7 amic acid, alanine, glycine, pyrimidine, and creatine.

8 ed by nutritional factors such as folate and creatine.

9 mino acids, neurotransmitters, osmolytes, or creatine.

10 ntly higher intracellular diffusion of total creatine (0.202 +/- 0.032 mum(2)/ms, P = 0.018) and tota

11 Participants were randomized to placebo or creatine (10 g/d) monohydrate for a minimum of 5 years (

12 mized to receive 400 mug FA, 800 mug FA, 3 g creatine, 3 g creatine+400 mug FA, or placebo daily.

13 ve 400 mug FA, 800 mug FA, 3 g creatine, 3 g creatine+400 mug FA, or placebo daily.

14 Creatine, a nitrogenous organic acid, replenishes cytopl

15 ter the RG diet, whereas melatonin, betaine, creatine, acetylcholine, aspartate, hydroxyproline, meth

16 We further demonstrated that creatine acts as a "molecular battery" conserving bioene

17 Remarkably, creatine administration into Gamt-deficient and wild-typ

18 ages/microglia into lesions, suggesting that creatine affects oligodendrocyte survival independently

19 studies, we will evaluate whether FA and/or creatine altered As methylation profiles.

20 on of homozygous Gatm mutants with exogenous creatine ameliorated the colitis phenotype.

21 Here, we investigated the role of creatine, an organic acid involved in adenosine triphosp

22 intracellular signals, and cyclocreatine, a creatine analog that can supply ATP.

23 of glutamate, glutamine, myo-inositol, NAA, creatine and choline.

24 Phosphocreatine/creatine and citrate were identified at higher concentra

25 measurement of the isotopic distribution of creatine and creatinine by liquid chromatography-tandem

26 y be affected by the interconversion between creatine and creatinine during sample preparation or by

27 rations of glutamate, taurine, myo-inositol, creatine and inosine were present in aqueous extracts an

28 anglia) N-acetylaspartate (NAA)/Choline, NAA/Creatine and myo-inositol/Creatine ratios were measured.

29 ifteen healthy adults were supplemented with creatine and placebo treatments for 7 d, which increased

30 coveries of other BAT futile cycles based on creatine and succinate have provided additional targets.

31 inositol (mI) and metabolic changes in total creatine and taurine previously reported to be associate

32 Total N-acetylaspartate, total creatine and total choline diffusion values from all pat

33 The higher diffusivity of total creatine and total choline in patients with NPSLE, as we

34 tions in creatine phosphate/ATP ratio, total creatine, and ATP-mirror changes observed in failing hea

35 , total choline-containing compounds (tCho), creatine, and glutamine and glutamate complex were estim

36 ict myocardial ATP, ADP, creatine phosphate, creatine, and inorganic phosphate concentrations as func

37 metabolism, including lipoproteins, glucose, creatine, and isoleucine.

38 ntrations of cytoplasmic adenine nucleotide, creatine, and phosphate pools that occur with aging impa

39 the amino acid arginine, the energy carrier creatine, and the nucleobase guanine.

40 fusivities of choline compounds and of total creatine are potentially unique markers for glial reacti

41 for the first time in humans, the utility of creatine as a dietary supplement to protect against ener

42 Therefore, our results have identified creatine as an important metabolic regulator controlling

43 n, we found that CRT regulates intracellular creatine, barrier formation, and wound healing.

44 umaric acid, inosine, inosine monophosphate, creatine, betaine, carnosine and hypoxanthine) out of ei

45 Herein, we highlight the latest advances in creatine biology in tissues and cell types that have his

46 A resurgence of interest in creatine biology is developing, with new insights into a

47 n arginine-glycine amidinotransferase in the creatine biosynthesis pathway.

48 e (GATM) catalyzes the rate-limiting step of creatine biosynthesis: the transfer of an amidino group

49 tients, levels were modestly lower for GABA+/creatine but did not differ for GABA+/water compared wit

50 nopus oocytes revealed that MCT12 transports creatine but not its precursor, guanidinoacetate.

51 Depletion of intracellular creatine by ablation of the creatine transporter Slc6a8

52 Patients in ARISTOTLE without severe renal (creatine clearance <=30 mL/min) or liver disease were in

53 function was the highest for RCV (0.58 with creatine clearance, 0.54 with estimated glomerular filtr

54 partate (NAA), choline-containing compounds, creatine-containing compounds (Cr), myo-inositol (mI), a

55 We observed a decrease in creatine content from the center of the meat piece to th

56 In adipose tissue, creatine controls thermogenic respiration and loss of th

57 age diffusivities of total choline and total creatine, correlate with systemic lupus erythematosus ac

58 n SAM-dependent metabolism of polyamines and creatine could not be directly attributed to alterations

59 te plus N-acetyl-aspartyl-glutamate (NAA) to creatine (Cr) and choline compounds (Cho) to Cr in wides

60 t this, we measured RSFC with fMRI and GABA+/Creatine (Cr) concentrations with proton magnetic resona

61 uronal mitochondrial function, normalized to creatine (Cr) levels were measured from the motor cortex

62 N-acetyl-aspartate (NAA), choline (Cho) and creatine (Cr).

63 f N-acetylaspartate (NAA), choline (Cho) and creatine (Cr).

64 e ratios (citrate [Cit], spermine [Spm], and creatine [Cr] to choline [Cho] and Cho to Cr plus Spm) w

65 The methodology was applied to study the creatine-creatinine interconversion during LC-MS/MS and

66 od capable of correcting and quantifying the creatine-creatinine interconversion occurring during the

67 s of real serum samples by GC-MS showed that creatine-creatinine separation by SPE can be a nonquanti

68 s, four metabolites significantly increased: creatine, dehydroascorbate, fumarate, and succinate in t

69 We found that creatine did not affect the recruitment of macrophages/m

70 ermally stable but less soluble comparing to creatine due to a self-aggregation process that occurs a

71 nation.SIGNIFICANCE STATEMENT We report that creatine enhances oligodendrocyte mitochondrial function

72 beige adipose signature and demonstrate that creatine enhances respiration in beige-fat mitochondria

73 treatment effects between the 400 ug FA and creatine + FA groups.

74 itamin D, with positive isolated studies for creatine, folinic acid, and an amino acid combination.

75 There has been recent interest in creatine for its neuroprotective effects in neurodegener

76 In the creatine group, the mean decrease in %MMAs exceeded that

77 N-acetylaspartate, choline, myo-inositol and creatine) group contrasts from all individual voxels tha

78 In the absence of adequate creatine, IECs transition toward a stressed, glycolysis-

79 spectroscopic findings of N-acetylaspartate/creatine in frontal gray matter (r = -0.40; P = .03), fr

80 ncover a previously uncharacterized role for creatine in macrophage polarization by modulating cellul

81 our results demonstrate a novel function for creatine in promoting oligodendrocyte viability during C

82 GABA+/creatine in the dorsal anterior cingulate may constitute

83 serve, yet little is known about the role of creatine in the immune system.

84 functions as a basolateral exit pathway for creatine in the proximal tubule.

85 gyri (16 voxels, CCLAV = 0.04) and increased creatine in two clusters involving left temporal, pariet

86 We found that creatine increased mitochondrial ATP production directly

87 monohydrate supplementation augments neural creatine, increases corticomotor excitability, and preve

88 Mechanistically, creatine inhibited the induction of immune effector mole

89 urface transporter controlling the uptake of creatine into a cell.

90 Also, a detectable conversion of creatine into creatinine was observed during sample prep

91 Creatine is a molecule that supports energy metabolism i

92 Creatine is a naturally occurring compound involved in t

93 Creatine is also neuroprotective in vitro against anoxic

94 H(+)-ATP synthase with ADP until glucose or creatine is available.

95 hypothesized that ATP transfer rate through creatine kinase (CK) (k(f)(CKrest)) would be increased,

96 s, but, to date, has not been confirmed with creatine kinase (CK) assays.

97 Our results show that routine creatine kinase (CK) blood values, plasma EVs physical c

98 We investigate the hypothesis that reduced creatine kinase (CK) capacity and flux is associated wit

99 a 2-tiered approach to NBS with screening by creatine kinase (CK) levels in dried blood spots followe

100 Serum creatine kinase (CK) levels were lower (p = 0.025), and

101 In addition, serum creatine kinase (CK) levels within the Oxford CMS cohort

102 iation of a recently reported variant in the creatine kinase (CK) muscle gene, CKM Glu83Gly (rs115590

103 lationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial band levels, and ske

104 erase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK), which cardiac troponins being the

105 Inhibition of creatine kinase (CK), which increases cytosolic ADP, in

106 re we report cryo-EM data for the substrate, creatine kinase (CKB) bound to ASB9-ELOB/C, and for full

107 common grade 3-4 adverse events were raised creatine kinase (five [6%] in the 200 mg group vs 19 [13

108 inol-binding protein (hRBP) under the muscle creatine kinase (MCK) promoter (MCKhRBP) with the PKCdel

109 o proceeded directly to phase B for elevated creatine kinase (N = 218, with 73 randomized to ezetimib

110 95% CI 1.34, 13.71; p = 0.014), and elevated creatine kinase (OR 3.79; 95% CI 1.06, 13.51; p = 0.04),

111 nfarction </=1 flow, there was reduced serum creatine kinase (P=0.030) and a 19% reduction in cardiac

112 e fibers, increased central nuclei, elevated creatine kinase activity and endomysial fibrosis.

113 fat, cold exposure stimulates mitochondrial creatine kinase activity and induces coordinated express

114 further explore the effect of calmodulin on creatine kinase activity and show that it is increased b

115 f differentiation, demonstrated by increased creatine kinase activity, fusion index and myotube diame

116 ne blood chemistry was normal, as were serum creatine kinase and aldolase levels and thyroid, hepatic

117 We also found that plasma creatine kinase and aspartate aminotransferase levels in

118 boratory analysis showed alteration of serum creatine kinase and creatinine in the Leu389Ser ALS4 coh

119 e cell number, and a decrease in activity of creatine kinase and several oxidative enzymes.

120 revascularization report reduced release of creatine kinase and troponin.

121 Of the 1,800 patients enrolled, 1,652 with creatine kinase and/or creatine kinase-myocardial band (

122 terquartile range, 14-42; P<0.01) and median creatine kinase areas under the curve were 22 000 and 38

123 variability compared with the commonly used creatine kinase assay, and correlated better with the re

124 y plus rifaximin group showed an increase in creatine kinase at the end of treatment compared with pa

125 gen species (mROS): hexokinases I and II and creatine kinase bound to mitochondrial membranes.

126 ll patients showed increased levels of serum creatine kinase but no or minor muscle weakness.

127 A 43 kDa band, identified as creatine kinase by proteomic analysis, showed the potent

128 identified the ATP-buffering, mitochondrial creatine kinase CKMT1 as necessary for survival of EVI1-

129 e dye uptake into muscle and increased serum creatine kinase compared to the 129T2/SvEmsJ background.

130 he most common adverse event was an elevated creatine kinase concentration to more than ten times the

131 Peak and area under the creatine kinase curve did not differ between both groups

132 , gastrointestinal effects, and asymptomatic creatine kinase elevation.

133 3 and miR-551a expression, which derepresses creatine kinase expression and allows energy to be captu

134 Creatine kinase expression falls, possibly impairing hig

135 nally, these mice exhibited increased plasma creatine kinase following exhaustive exercise when unfed

136 ne kinase reaction, we have now measured the creatine kinase forward reaction rate constant in BD.

137 We found a significant reduction in creatine kinase forward reaction rate constant in the BD

138 hy control participants at 4T and quantified creatine kinase forward reaction rate constant using (31

139 Creatine kinase from salmon and catfish was detected by

140 on by OXPHOS (vOX), anaerobic glycolysis and creatine kinase in moderate and severe intensity exercis

141 We observed no significant changes in creatine kinase in the simvastatin 20 mg/day plus rifaxi

142 resonance-determined myocardial salvage and creatine kinase kinetics.

143 common grade >= 3 event was increased blood creatine kinase level (26%).

144 The median creatine kinase level was 5326 U/L.

145 = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 t

146 cle degeneration, but had no effect on serum creatine kinase levels and muscle strength.

147 , Evans blue dye uptake is reduced and serum creatine kinase levels are lower.

148 These programs used elevated creatine kinase levels in dried blood spots for the init

149 Elevated creatine kinase levels in the neonatal period are the in

150 ' muscle biopsies were dystrophic, and serum creatine kinase levels were 1,050 to 9,200U/l.

151 Muscle MRI and serum creatine kinase levels were normal.

152 distribution and significantly reduced serum creatine kinase levels, but had limited effect on muscle

153 ut without an earlier onset, increased serum creatine kinase levels, or decreased muscle strength.

154 e disorder associated with elevated neonatal creatine kinase levels.

155 esonance imaging, and through elevated serum creatine kinase levels.

156 Fractional synthesis rate (FSR) of plasma creatine kinase M-type (CK-M) and carbonic anhydrase 3 (

157 NAME induced elevation of cardiac output and Creatine Kinase Muscle-Brain (CKMB), but had no signific

158 ts, there was a reduction in serum levels of creatine kinase muscle-brain isoenzyme, a myocardial-spe

159 ted by targeted replacement of mitochondrial creatine kinase or mitochondrial-targeted CaMKII inhibit

160 Thirty-one of 34 patients had elevated creatine kinase or myoglobin.

161 e overexpressing PGC-1alpha under the muscle creatine kinase promoter (MPGC-1alphaTG mice) displayed

162 is replenished from phosphocreatine via the creatine kinase reaction, we have now measured the creat

163 No evidence of differences in creatine kinase release (P=0.92), troponin T (P=0.85), o

164 y (31)P nuclear MR spectroscopy, lactate and creatine kinase release spectrophotometrically, and hypo

165 ed muscle degeneration and fibrosis, reduced creatine kinase serum levels, restored running capacity

166 Diagnosis using the classic blood marker creatine kinase sometimes yields unsatisfactory results

167 olipoprotein A1 (apoA1), apoE, mitochondrial creatine kinase U-type, beta-synuclein, synaptogyrin-3,

168 Creatine kinase values in these animals are increased an

169 Serum creatine kinase values were usually normal or slightly e

170 Creatine kinase was normal or mildly elevated, and muscl

171 tions of serum transaminases, bilirubin, and creatine kinase were infrequent and similar between grou

172 catalytic site of bound hexokinase or bound creatine kinase without ATP dilution in the cytosol.

173 h large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, prob

174 ased lactate dehydrogenase, pyruvate kinase, creatine kinase, and cytochrome c oxidase activities, an

175 derived from lactate dehydrogenase, one from creatine kinase, and four from serum albumin protein.

176 f three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

177 size distribution, centralized nuclei, serum creatine kinase, and quantitative histopathology scores.

178 f such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke di

179 e levels of creatine kinase, MB isoenzyme of creatine kinase, blood urea nitrogen, creatinine, K(+) i

180 These miRNAs convergently target creatine kinase, brain-type (CKB), which phosphorylates

181 ants or isoforms of tropomyosin, arginine or creatine kinase, glyceraldehyde-3-phosphate dehydrogenas

182 ice exhibited progressive MD, elevated serum creatine kinase, heart dilation, blood vessel irregulari

183 ved hemodynamics and decreased the levels of creatine kinase, MB isoenzyme of creatine kinase, blood

184 st notably the regions harboring CKMT2 gene (creatine kinase, mitochondrial 2) and RASGRF2 gene (Ras

185 arkers included high-sensitivity troponin T, creatine kinase, myoglobin, N-terminal B-type natriureti

186 intra- and intermolecular cross-links within creatine kinase, then to map the interaction surfaces be

187 erize the interaction between calmodulin and creatine kinase, which we identify as a novel calmodulin

188 rs including troponin I or T (cTnI or cTnT), creatine kinase-MB (CK-MB), and myoglobin.

189 MI (PMI(Prot)) required a large elevation of creatine kinase-MB (CK-MB), with identical threshold for

190 rocedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas t

191 models and included haptoglobin, IL-10, and creatine kinase-MB.

192 enrolled, 1,652 with creatine kinase and/or creatine kinase-myocardial band (CK-MB) post-procedure w

193 The area under the creatine kinase-myocardial brain fraction curve was 3144

194 ficulties, and normal to moderately elevated creatine kinase.

195 aminotransferase, lactate dehydrogenase, and creatine kinase.

196 thesis from OXPHOS, anaerobic glycolysis and creatine kinase.

197 assessed by cardiac enzymes, troponin I, and creatine kinase.

198 including fasciculations and elevated serum creatine kinase.

199 ansferase [ALT]), alkaline phosphastase, and creatine kinase.

200 but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and

201 Myoglobin, creatine-kinase (CK) showed increased levels at the star

202 ir of high-energy phosphate (HEP) bonds, and creatine kinases (CK) catalyze the transfer of HEP from

203 istidine, xanthurenate, isovalerylcarnitine, creatine, kynurenate, 1-(1-enyl-palmitoyl)-2-arachidonoy

204 the stomach) of alanine, choline compounds, creatine, leucine and valine.

205 and -1.6 ppm, likely arising from changes in creatine level and nuclear overhauser effects, which wer

206 Creatine levels are maintained by diet and endogenous sy

207 Pharmacological reduction of creatine levels decreases whole-body energy expenditure

208 erformance liquid chromatography (to measure creatine levels), qRT-PCR, transepithelial electrical re

209 FCVRS was also negatively correlated with creatine levels, again primarily in white matter.

210 al excretion of guanidinoacetate, but normal creatine levels, suggesting that MCT12 may function as a

211 tricular enlargement and reduced MRS-derived creatine levels.

212 S metabolite peak-area ratios (n=160) of NAA-creatine (<1.29) had an AUC of 0.79 (0.72-0.85), of NAA-

213 The branched-chain amino acids, creatine, lysine, 2-aminobutyrate, glutamine, glycine, t

214 effect is manifested through both UCP1- and creatine-mediated mechanisms.

215 We identify arginine/creatine metabolism as a beige adipose signature and dem

216 Suppression of arginine-creatine metabolism by CKMT1-directed shRNAs or by the s

217 We also cover the various roles that creatine metabolism has in cancer cell survival and the

218 al that lies in understanding how changes in creatine metabolism lead to metabolic disease.

219 These findings link a futile cycle of creatine metabolism to adipose tissue energy expenditure

220 'Benzoate metabolism', 'ceramides', 'creatine metabolism', 'fatty acid metabolism (acyl carni

221 lism, membrane lipid breakdown and increased creatine metabolism.

222 rdinated expression of genes associated with creatine metabolism.

223 domized placebo-controlled clinical trial of creatine monohydrate (10 g/d) that was performed at 45 s

224 nd treated Parkinson disease, treatment with creatine monohydrate for at least 5 years, compared with

225 These findings do not support the use of creatine monohydrate in patients with Parkinson disease.

226 Dietary creatine monohydrate supplementation augments neural cre

227 ical shift imaging (CSI) was used to explore creatine-normalized measures of other metabolites in bas

228 bo treatments for 7 d, which increased brain creatine on average by 9.2%.

229 ed proteins or macromolecules) referenced to creatine or water were studied with J-edited proton spec

230 anserine (p=0.034), carnosine (p=0.019) and creatine (p=0.049).

231 eatine-mediated reactivation of the arginine-creatine pathway.

232 to receive FA (400 or 800 mug per day), 3 g creatine per day, 400 mug FA + 3 g creatine per day, or

233 day), 3 g creatine per day, 400 mug FA + 3 g creatine per day, or placebo.

234 Creatinine is a metabolic product of creatine phosphate in muscles, which provides energy to

235 l energetics to predict myocardial ATP, ADP, creatine phosphate, creatine, and inorganic phosphate co

236 ergetics associated with aging-reductions in creatine phosphate/ATP ratio, total creatine, and ATP-mi

237 A higher creatine phosphate:ATP ratio in diabetic kidney cortices

238 acetylaspartate, and the predominantly glial creatine + phosphocreatine and choline compounds.

239 of N-acetyl compounds, glutamate+glutamine, creatine+phosphocreatine, and choline compounds in 78 ch

240 of N-acetyl compounds, glutamate+glutamine, creatine+phosphocreatine, or choline compounds measured

241 of 179), anaemia (ten [6%]), increased blood creatine phosphokinase (12 [7%]), and fatigue (eight [4%

242 ty population in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the

243 CKM Glu83Gly (rs11559024) with constitutive creatine phosphokinase (CK) levels, CK variation, and in

244 lity, time to microbiological clearance, and creatine phosphokinase (CPK) elevation.

245 vent in the upadacitinib group was increased creatine phosphokinase (eight [9%] of 93 patients in the

246 rade 3 or worse adverse events were elevated creatine phosphokinase (five [10%]) and maculopapular ra

247 nd 200 mg twice a day) and grade 4 increased creatine phosphokinase (n = 1; 150 mg once daily).

248 h autoimmune disorder (n=3), increased blood creatine phosphokinase (n=2), and increased aspartate am

249 [11%] in treatment group B), increased blood creatine phosphokinase (one [1%] vs four [4%]), and hypo

250 laboratory values, including increased blood creatine phosphokinase (seven [8%]), increased alanine a

251 ffect was an asymptomatic increase in plasma creatine phosphokinase concentration (200 mg, n=5; 400 m

252 (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite

253 es were uncommon, except for 15 increases in creatine phosphokinase in 14 participants (three partici

254 and one patient at 20 mg/kg, increased blood creatine phosphokinase in two patients at 20 mg/kg, and

255 in the placebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]),

256 patients: lymphopenia in two patients, blood creatine phosphokinase increase in one patient, aminotra

257 or diarrhea; an asymptomatic increase in the creatine phosphokinase level; acneiform rash; and parony

258 ete blood count and electrolyte, creatinine, creatine phosphokinase, and troponin T levels were norma

259 dividuals had eye defects or elevated muscle creatine phosphokinase, separating the TMTC3 COB phenoty

260 dition of oligomycin A, phosphocreatine, and creatine phosphokinase.

261 te [eGFR] <60 ml/min/1.73 m(2) or albumin-to-creatine ratio >300 mg/g).

262 cetylaspartate and N-acetylaspartylglutamate/creatine ratio (NAA/Cr) in a group of 89 women with CFS.

263 ptimized MEGA-PRESS editing sequence and GSH/creatine ratios were calculated for DLPFC (SZ: n = 33, H

264 (NAA)/Choline, NAA/Creatine and myo-inositol/Creatine ratios were measured.

265 Creatine regulates energy distribution within cells and

266 ic, and immunological analyses revealed that creatine reprogrammed macrophage polarization by suppres

267 This is the first demonstration of creatine's utility as a neuroprotective supplement when

268 GABA+/creatine showed a modest degree of familiality (intracla

269 the placebo group at wk 6 and 12 (P < 0.05); creatine supplementation did not affect change in %InAs

270 Dietary creatine supplementation has been associated with improv

271 o determine whether 400 or 800 mug FA and/or creatine supplementation lowers bAs in an As-exposed Ban

272 is study was to assess the influence of oral creatine supplementation on the neurophysiological and n

273 igated the effects of folic acid (FA) and/or creatine supplementation on the proportion of As metabol

274 cell immunity, underscoring the potential of creatine supplementation to improve T cell-based cancer

275 e mouse tumor models, and the combination of creatine supplementation with a PD-1/PD-L1 blockade trea

276 pacity, were restored when participants were creatine supplemented, and corticomotor excitability inc

277 Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors,

278 iated demyelination in mice deficient in the creatine-synthesizing enzyme guanidinoacetate-methyltran

279 (8.1 +/- 0.2 vs 9.4 +/- 0.4; P < .01), total creatine (tCr) (7.5 +/- 0.2 vs 8.3 +/- 0.3; P < .01), an

280 for mIns in hippocampus and thalamus, total creatine (tCr) and tCho in ACC and hippocampus; lower le

281 choline relative to each other and to total creatine (tCr) were obtained from usable spectra.

282 ch is mainly localized in neurons, and total creatine (tCr), an energy metabolite, in 19 BD patients

283 olic fate of L-arginine is the generation of creatine that acts as a key source of cellular energy re

284 13)C analogues ((13)C1-creatinine and (13)C2-creatine), the measurement of the isotopic distribution

285 Supplementing creatine to WT mice significantly suppressed tumor growt

286 e (CKB), which phosphorylates the metabolite creatine, to generate phosphocreatine.

287 MCT12 (also known as SLC16A12) that mediates creatine transport was recently identified as the cause

288 Creatine Transporter Deficiency (CTD) is an inborn error

289 tic investigation of the distribution of the creatine transporter in the human brain.

290 of intracellular creatine by ablation of the creatine transporter Slc6a8 altered macrophage-mediated

291 We studied the functions of the creatine transporter solute carrier family 6 member 8 (S

292 is carried across the plasma membrane by the creatine transporter.

293 ts enrolled in the Bangladesh Folic Acid and Creatine Trial (FACT).

294 Using CrT knockout mice, we showed that creatine uptake deficiency severely impaired antitumor T

295 A neuromodulatory effect of creatine via increased energy availability is presumed t

296 placebo was 2360 (95% CI, 2249-2470) and for creatine was 2414 (95% CI, 2304-2524).

297 However, creatine was higher in antipsychotic-treated vs HC's in

298 Creatine was not different between the two groups.

299 neurochemical measure, myo-inositol+glycine/creatine, was consistently increased in each brain regio

300 the distribution indicates that supplemented creatine would be widely taken up by brain cells, althou